Hepatitis B Flares
In China VTI-301 phase 3 clinical trial, ELAD treatment was well-tolerated by Chinese subjects with ACLF predominately secondary to chronic viral hepatitis B alone or in combination with alcoholic liver disease. Results demonstrate a significant improvement in transplant-free survival (TFS) in ELAD versus Control groups in association with significant improvements in serum bilirubin levels presumably related to the improvement of hepatic function.2 In Singapore, ELAD was utilized as a compassionate use to treat liver failure patients. The overall results in 8 patients were successful and all patients suffered hepatitis B flares, 4 smoothly went to living donor liver transplant after 7 days of ELAD treatment. Four recovered without the transplant.
Address: floor 1, block B (21b), neijuxuan workshop, comprehensive bonded zone, No. 33688, jingshidong Road, Jinan area, China (Shandong) pilot Free Trade Zone Telephone:
Copyright: Shandong yiruite Biotechnology Co., Ltd Record No:鲁ICP备20021086 Sign in